Platform & Pipeline


Our lead candidate from our platform, CRLX101, is an NDC with a camptothecin payload. Camptothecin is a potent topoisomerase 1 inhibitor that was too toxic to develop clinically; however, we believe that CRLX101 appears to reduce the toxicities associated with camptothecin, while increasing the payload concentration in tumors. We believe that the patients and their physicians would welcome a better tolerated and more active topoisomerase 1 inhibitor than the current marketed topoisomerase 1 inhibitors.

CRLX101 has been studied in over 400 patients and has demonstrated clinical activity in multiple tumor types as monotherapy and in combination with other anti-cancer agents.